Gefitinib may be effective to treat esophageal cancer in some patients
the ONA take:
According to new research published in The Lancet Oncology, gefitinib, a drug already used to treat lung cancer, may be effective to treat esophageal cancer in a small subgroup of patients. In the Cancer Oesophagus Gefitinib study, researchers tested gefitinib in patients with esophageal cancer who had progressed after chemotherapy.
The study showed that gefitinib had minimal impact on most patients and only increased survival rates by a small amount; however, the drug did drastically improve the quality of life, survival duration, and symptom control in about 15% of patients. The main adverse effect was diarrhea.
Russell Petty, PhD, of the University of Aberdeen in Aberdeen, Scotland and senior researcher of the study said that the patients who improved on gefitinib did so within a few weeks of initiating therapy and some patients had disease control for almost 2 years. Dr. Petty notes that not all patients with esophageal cancer should be offered gefitinib and that there is a need for a test to screen whether a patient would improve on gefitinib.
Gefitinib (Iressa), a tyrosine kinase inhibitor, was approved in 2003 by the U.S. Food and Drug Administration to treat advanced EGFR mutation-positive non-small cell lung cancer.
Findings of a trial could lead to a new treatment approach for oesophageal cancer.
The University of Aberdeen was involved in a UK wide study to see if the drug gefitinib - already used in lung cancer - could help treat oesophageal cancer.
The Cancer Oesophagus Gefitinib trial was the first study conducted in oesophageal cancer patients whose disease had progressed after chemotherapy.
- Response to Anemia Treatment Differs in Lymphoma, Multiple Myeloma
- Fertility Preservation in Male Adolescents and Young Adults With Cancer
- Impact of Prostate Cancer Diagnosis, Treatment Choice on Quality of Life
- Social, Psychiatric Variables Reduce Cognitive Functioning, QoL in HNC
- Axillary Lymph Node Dissection Predictive for Lymphedema in Breast Cancer
- HPV and Cancer (Fact Sheet)
- Pain Control More Easily Achieved With Nurse-Led Education in Bone Metastases
- Acupuncture an Effective Alternative Treatment for Cancer-Related Fatigue
- Using Nutrition-Based Strategies to Manage Adverse Effects of Cancer
- Palliative Care Associated With Decreased Costs For Patients With Advanced Cancer
- Refined Equation May Obviate Oncotype DX in Breast Cancer Treatment Decisions
- Risk Factors for Brain Metastases in HER2+ Breast Cancer Identified in Analysis
- Intermediate Oncotype DX Scores Prognostic of OS in Early-stage Breast Cancer
- Colorectal Cancer and Dietary Fiber: Source Is More Important Than Amount
- Reduced Delayed Intensification Impacts Risk of Pediatric ALL Relapse
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|